Xentuzumab is a humanized, IGF-1 and IGF-2 neutralizing antibody that has been tested in combination with everolimus and exemestane in a phase Ib/II trial of advanced, ER+ breast cancer. The gene discussed is IGF1; the disease is breast cancer.